PEPTECH PARTICIPATES IN DOMANTIS CAPITAL RAISING

Australian biotechnology company Peptech Limited (ASX: PTD) today announced it had increased its investment in UK drug development company Domantis Limited in a GBP 17 million (A$39.5 million) capital raising that had attracted two significant new shareholders. Domantis raised the funds from new investors Novo Nordisk and Mitsubishi subsidiary MC Life Science Ventures, Inc*, together with existing investors, to fund the ongoing clinical development of the company's 12 domain antibody (dAb) programs.

Biotech Intelligence (http://www.biotech-intelligence.com/html/html/3f1f4adb698cd9ab7216a1d91180b027.html)